Atara still can't get across the US finish line
Just when investors thought things couldn't get any worse, they do.
Nuvalent sets out its two-pronged strategy
In ALK-positive NSCLC Nuvalent is starting a first-line phase 3, but the ROS1 path could be easier.
Licensed assets enter the clinic
The latest first-in-human trial initiations include projects licensed in by Gilead and Context.
Regeneron’s lung cancer Lag3 lag
Fianlimab NSCLC data are delayed, while odronextamab gets a DLBCL blow.
